Literature DB >> 20851052

LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango?

Shahar Kol1, Peter Humaidan.   

Abstract

Until now, clinicians have been relying solely on LH activity-dependent triggering of final oocyte maturation and thus taken it for granted that the natural midcycle FSH surge is biologically redundant. However, it is time to question this paradigm. Evidence from clinical studies hint that in a yet-to-be-defined subset of patients, dual LH and FSH surge is advantageous compared with LH-only surge in the form of human chorionic gonadotrophin (HCG) trigger. Dual surge can be triggered by a bolus of gonadotrophin-releasing hormone agonist causing a flare-up of both endogenous LH and FSH, resembling the natural midcycle surge of gonadotrophins. HCG given in parallel secures adequate exposure to LH activity. Further research is needed to characterize the patients in whom FSH surge is needed for proper resumption of the oocyte meiotic process.
Copyright © 2010 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851052     DOI: 10.1016/j.rbmo.2010.06.031

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  12 in total

1.  FSH Regulates mRNA Translation in Mouse Oocytes and Promotes Developmental Competence.

Authors:  Federica Franciosi; Shila Manandhar; Marco Conti
Journal:  Endocrinology       Date:  2015-12-10       Impact factor: 4.736

2.  Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series.

Authors:  Bülent Gülekli; Funda Göde; Zerrin Sertkaya; Ahmet Zeki Işık
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

3.  GnRH triggering may improve euploidy and live birth rate in hyper-responders: a retrospective cohort study.

Authors:  Justin Tan; Chen Jing; Lisa Zhang; Jasmine Lo; Arohumam Kan; Gary Nakhuda
Journal:  J Assist Reprod Genet       Date:  2020-06-13       Impact factor: 3.412

4.  A matched propensity score study of embryo morphokinetics following gonadotropin-releasing hormone agonist versus human chorionic gonadotropin trigger.

Authors:  Galia Oron; Onit Sapir; Avital Wertheimer; Yoel Shufaro; Roni Bar-Gil; Tamar Margalit; Ekaterina Shlush; Avi Ben-Haroush
Journal:  J Assist Reprod Genet       Date:  2020-09-27       Impact factor: 3.412

5.  A new approach for ovarian stimulation in IVF using Corifollitropin Alfa in combination with GnRH analogues to trigger final oocyte maturation. A pilot study.

Authors:  W Decleer; K Osmanagaoglu; G Meganck; P Devroey
Journal:  Facts Views Vis Obgyn       Date:  2014

6.  Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial.

Authors:  W Decleer; K Osmanagaoglu; B Seynhave; S Kolibianakis; B Tarlatzis; P Devroey
Journal:  Facts Views Vis Obgyn       Date:  2014

7.  GnRH agonist triggering affects the kinetics of embryo development: a comparative study.

Authors:  Ali Sami Gurbuz; Funda Gode; Mehmet Sukru Uzman; Betul Ince; Melek Kaya; Necati Ozcimen; Emel Ebru Ozcimen; Ali Acar
Journal:  J Ovarian Res       Date:  2016-04-08       Impact factor: 4.234

8.  Comparing the effect of gonadotropin-releasing hormone agonist and human chorionic gonadotropin on final oocytes for ovulation triggering among infertile women undergoing intrauterine insemination: An RCT.

Authors:  Robabeh Taheripanah; Marzieh Zamaniyan; Atefeh Moridi; Anahita Taheripanah; Narges Malih
Journal:  Int J Reprod Biomed       Date:  2017-06

Review 9.  Resurgence of Minimal Stimulation In Vitro Fertilization with A Protocol Consisting of Gonadotropin Releasing Hormone-Agonist Trigger and Vitrified-Thawed Embryo Transfer.

Authors:  John Zhang
Journal:  Int J Fertil Steril       Date:  2016-06-01

Review 10.  Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention.

Authors:  Juan Carlos Castillo; Thor Haahr; María Martínez-Moya; Peter Humaidan
Journal:  Ups J Med Sci       Date:  2020-03-25       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.